{‘She has zero experience’: this US healthcare community girds for Dr. Høeg's tenure at the Food and Drug Administration.

As the United States proceeds with sweeping revisions to its vaccination recommendations, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots in the pandemic and has concentrated on potential deaths following Covid vaccination in her brief tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Health officials had intended to reveal major changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of alignment with a large portion of the world with little proof for benefit. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s CDER, the fifth appointee to lead the office this year.

A Shift at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting specific pediatric immunization guidelines in the US in order to be more in line with Denmark, a society with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – as opposed to medication approval.

Questions Over Expertise

Høeg has no obvious experience in drug development, regulation or leadership, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who ran CBER have had.”

CDER has an immense range of responsibilities at the agency, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and every single one need to be managed,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a significant management element to the role, which oversees more than 5,000 staff members. “It’s a huge leadership role, if you execute it properly,” she said.

Response and Controversial Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this appointment represents greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “concerns stem from flawed presumptions”.

“Her resume is consistent with the responsibilities of her job,” the spokesperson explained, noting the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial expedited therapy clearance system that allegedly worried her former heads. “How are these therapies being chosen for this expedited pathway? Who takes the decisions?” Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

Overall, he said, “the agency looks to be trending towards less stringent regulations of pharmaceuticals, aside from immunizations.”

Public Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, critics have noted. She released a analysis using non-validated crowd-sourced reports to determine the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new administration encompassed altering guidelines for recently developed shots and ending “optional” vaccines, she remarked after the election on a online show. At the FDA, Høeg has allegedly suggested excluding young men from getting Covid vaccinations.

“She’s an thorough true believer who commences with her conclusions and reverse-engineers to retrofit the science in a highly disingenuous, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined fellow skeptics, {like|